Therapeutic Agent for Asthma Using IL-6 Inhibitor

EPO granted Patent EP3747469A1 for a therapeutic agent comprising an IL-6 (interleukin-6) inhibitor for treating asthma. The patent application claims compositions including anti-IL-6 receptor antibodies and pharmaceutical formulations suitable for asthma treatment (A61P 11/06). The designated states cover all EU member states including DE, FR, GB, IT, ES, NL, BE, AT, SE, DK, FI, PL, CZ, HU, PT, RO, BG, HR, SI, SK, LT, LV, EE, LU, MT, CY, IE, and IS.

For pharmaceutical manufacturers and biotech companies developing IL-6 targeted therapies for respiratory diseases, this patent creates potential blocking IP that may require licensing or design-around strategies. Companies with existing IL-6 or IL-6R antibody programs should assess whether their compositions or methods of use fall within the scope of these claims.